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Abstract Phospholipase C (PLC)-yl and -3,2 play a pivotal role 
in signal transduction for cell proliferation and differentiation. 
The enzyme activity and protein level of PLC-yI were markedly 
decreased in the human histiocytic leukemia U937 cell line during 
the differentiation process which is induced by phorbol 12-myris- 
tate 13-acetate (PMA) but those of PLC-y2 were not altered. 
Northern blot analysis showed that the levels of PLC-y1 and -y2 
transcripts were not changed. These results suggest hat the ex- 
pression of PLC-yI during the PMA-induced differentiation may 
be down-regulated by post-transcriptional processing. 
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adenomatous polyposis [8], supporting the view that PLC-yl 
plays an important role in controlling cellular proliferation. 
The human cell line U937 [9], when cultured in the presence 
of phorbol 12-myristate 13-acetate (PMA), undergoes growth 
arrest and promotes terminal differentiation from monoblasts 
to monocyte/macrophage-like cells [10,11]. It is important to 
elucidate the molecular mechanism inducing the growth arrest 
of differentiated cells. However, little is known about which 
molecules regulate the inhibition of cell growth in differentiated 
cells. In this study, to determine which PLC-y isozymes are 
involved in differentiation-induced llular growth arrest, we 
examined the change of the expression level of PLC-yl and 
PLC-y2 in PMA-treated U937 cells as a function of time. 
1. Introduction 
Phosphoinositide-specific phospholipase C (PLC) catalyzes 
the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) 
and thereby produces the intracellular messenger molecules, 
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DG) in 
response to the binding of various ligands to their surface 
receptors in signal transduction pathway [1]. Several distinct 
PLC isozymes have been purified and cloned from a variety of 
mammalian tissues [1]. Among the three known types of PLC 
isozymes (PLC-fl, -),, -~), the PLC-?~ isozymes contain the src 
homology domains (SH2 and SH3) in addition to common X 
and Y regions found in all the PLC isozymes [1]. 
PLC-yl is activated by phosphorylation f specific tyrosine 
residues by growth factor receptors with intrinsic tyrosine ki- 
nase activities uch as platelet-derived growth factor (PDGF) 
receptor [2], epidermal growth factor (EGF) receptor [3], fi- 
broblast growth factor (FGF) receptor [4]. These data imply 
that the activation of PLC-),I might be one of the important 
pathways involved in mitogenic signals triggered by these 
growth factors. Some evidences have also demonstrated that 
PLC-yl participated in cellular growth signal transduction. 
Smith et al. [5] found that microinjection fPLC-yl into quies- 
cent NIH 3T3 cells induced the acute dose-dependent induction 
of DNA synthesis. Moreover, the experiments with PDGF 
receptor mutants that fail to associate with some signaling 
molecules confirmed the possible role of PLC-yl as down- 
stream effector of mitogenic signal triggered by PDGF [6]. 
Recently, we have found that PLC-yl is highly expressed in 
human tissues obtained from colorectal cancer [7], and familial 
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2. Materials and methods 
2.1. Materials 
PMA, Pansorbin and wheat germ phosphatidylinositol were pur- 
chased from Calbioehem (San Diego, CA). 3-Phosphatidyl[2-3H]inosi - 
tol (17.9 Ci/mmol) were purchased from Amersham (Arlington 
Heights, IL). Alkaline phosphatase-conjugated ntibodies to mouse 
IgG were from Kirkegaard & Perry Inc. (Gaithersburg, MD). 
2.2. Cell culture 
U937 cells were cultured in RPMI 1640 medium (Life Technologies; 
Grand Island, NY) supplemented with 10% heat-inactivated bovine calf 
serum (Hyclone, Logan, UT). 
2.3. Induction of differentiation 
Differentiation of U937 cells was induced by adding 5 nM PMA 
(Calbiochem, San Diego, CA) as described [10,11]. Cell proliferation 
was checked by counting the viable cell with Trypan blue dye exclusion. 
Differentiation i to macrophage-like cells was assessed by morphology 
and by nitroblue tetrazolium (NBT) assay as described previously [12]. 
2.4. Immunoprecipitation and immune complex activity assay 
For immunoprecipitation, monoclonal ntibodies to PLC-yl [13] or 
PLC-~'2 (Lee, Y.H. et al., unpublished data) were prepared as described 
previously. Cells (7 x 106) were lysed with 20 mM HEPES, pH 7.2, 
containing 1% Triton X-100, 10% glycerol, 150 mM NaC1, 10 ¢tg/ml 
leupeptin, 1 mM phenylmethylsulfonyl fluoride and 7/,tg each of mon- 
oclonal antibodies toPLC-yl or PLC-y2 was added to the lysates. Alter 
incubation for 30 min in an ice-bath, 30/tl of 20% solution of formaline- 
fixed Staphylococcus aureus cells (Pansorbin; Calbiochem, San Diego, 
CA) precoated with rabbit anti-mouse Ig(Sigma, St. Louis, MO) were 
added and incubated for 2 h in an ice-bath. For the enzyme activity 
assay of PLC-yl and PLC-y2, immunoprecipitates w re prepared as 
described above. After washing three times with a buffer containing 20 
mM Tris-HCl (pH 7.4), 150 mM NaC1, 1 mM PMSF, immunecom- 
plexes were resuspended in 100/zl of the same buffer. The enzyme 
activity of PLC-71 or PLC-y2 was determined in the 200/zl assay 
mixture containing 50 ,uM PI (20,000 cpm, [3H]PI), 1 mM EGTA, 10 
mM CaCI2, 0.1% sodium deoxycholate, 50mM HEPES (pH 6.8) and 
10 ml of resuspended immunecomplexes. The assay mixture was incu- 
bated with at 37°C for 10 min and terminated as described previously 
[141. 
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2.5 Western blot analysis 
For the Western blot analysis, immunoprecipitates were prepared as 
described above. The immunecomplexes were washed five times with 
50 mM Tris-HC1, pH 8.5, 1% Triton X-100, 1% sodium deoxycholate, 
0.1% SDS and 150 mM NaC1. The precipitated proteins were heated 
at 95°C for 3 min with Laemmli cooking buffer and resolved by 8% 
SDS-PAGE, transferred to nitrocellulose, and proved with the indi- 
cated monoclonal antibodies for 4 h. Immunoreactive proteins were 
incubated with alkaline phosphatase conjugated goat anti-mouse 
IgG + IgA + IgM (1:2,000; Kirkegaard and Perry Lab.) and developed 
with 5-bromo-4-chloro-3-indoyl phosphate/nitro blue tetrazolium sub- 
strate system (Kirkgaard and Perry, Gaithersburg, MD) as described 
previously [8]. 
2.6. Radioimmunoassay 
To determine the protein level of PLC-yl or -72 in the control or 
differentiated cells, radioimmunoassay was performed according to the 
method as described by Suh et al. [18]. Briefly, the primary antibody- 
coated 96-well microtiter plates (Immulon-2) were prepared by adding 
1.5/.tg of each monoclonal ntibody (anti-PLC-yl, F7-2; anti-PLC-y2, 
y2-1-4) per well. After blocking the unsaturated plastic surface with 
0.5% bovine serum albumin, 50/al of various concentrations of purified 
PLC-71 or -?'2 standard and crude cell lysates (100 ~tg/ml) were added 
to the wells and incubated for 2 h at 37°C. Cell lysates were prepared 
as described in immunoprecipitation a d immunecomplex activity 
assay. After the plates were washed five times with phosphate-buffered 
saline containing 0.05% Tween-20, secondary antibody (anti-PLC-yl, 
D7-3; anti-PLC-?'2, ?'2-2-3) labeled with ~25I (20,000 cprn/well) was 
added and incubated for 4 h at room temperature. After five washing 
with above buffer, ~2SI-radioactivity of each well was measured. Stand- 
ard PLC-?'I or -?'2 was purified from HeLa cell extracts overexpressing 
each PLC isozymes by using vaccinia virus expression system. Second- 
ary antibody was radioiodinated using IODO-BEADS (Pierce Chemi- 
cal Co.) according to the manufacturer's instructions. 
2. 7. Northern blot analysis 
Total RNA was extracted from U937 cells treated without or with 
PMA for 72 hours using acid phenol method as described by 
Chomoczynski and Saccai [15]. Fifteen/lg of total RNA was separated 
on 1% agarose formaldehyde gel and blotted onto nylon membrane. 
Hybridization and washing were performed in the conditions described 
by Church and Gilbert [16]. Briefly, the membrane was incubated in the 
hybridization solution (1% bovine serum albumin, 7% SDS, 0.5 M 
NaHzPO4, pH 7.0, 1 mM EDTA, 2 x 106 cprrdm132p-labeled probe) at 
65°C overnight. Washing was performed in 0.1% SDS and 1 x SSC at 
70°C for 1 h. The membrane was exposed to X-ray film to identify the 
bands. 
3. Results and discussion 
PLC-71 and -72 are well known substrates of some growth 
factor receptor kinases [24] and are involved in the cellular 
growth signaling [5-8]. Although it is generally accepted that 
activation of PLC-~'I causes induction of DNA synthesis and 
cellular proliferation [5,6], the relationship between the expres- 
sion of PLC-7 isozymes and cellular differentiation has not 
been elucidated well. We have used the human U937 histiocytic 
leukemia cell line to study the role of expression of PLC-y  1 and 
-~2 during differentiation of hematopoietic cells. When treated 
with PMA, U937 cells can be induced to differentiate along a 
monocyte/macrophage pathway [10,11]. In this experiment, 
PMA-induced differentiation was monitored by morphological 
change, viable cell counting and NBT reduction assay (data not 
shown). In order to see whether differentiation of U937 cells 
modulates the PLC-y l  and -y2 activities, we examined PLC 
activity in immunecomplex. After exposure of U937 cells to 
PMA for various periods of times, extracted proteins were 
immunoprecipitated with monoclonal antibodies to PLC-y l  or 
-y2 , and then PI-hydrolyzing activity in immunoprecipitates 
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Fig. 1. Effect of PMA on U937 cells. A, U937 cells were treated with 
5 nM PMA for various times. After immunoprecipitation of cell ex- 
tracts with anti-PLC-yl (1) or anti-PLC-?'2 (m) antibody, enzyme activ- 
ity in immunecomplex was measured in the assay mixture containing 
50 ~M PI (20,000 cpm, [3H]PI) and immunecomplexes at 37°C 
(mean + S.D., n = 3). B, U937 cells were seeded at a concentration of
2 x 106 cells and treated without (1) or with (m) 5 nM PMA for various 
times. On the hours noted, viable cells were counted in a hemocytome- 
ter chamber. Viability was determined by 0.1% Trypan blue dye exclu- 
sions. 
was measured. After 24 h of PMA treatment, a significant 
decrease of PLC-71 activity was observed (Fig. 1A). The de- 
crease was even more significant after 60 h treatment with 
PMA. The activity of PLC-y l  was 81.2 + 4.2% and 30.0 + 5.0% 
of control after 24 and 48 h treatment with PMA, respectively. 
In contrast, no significant change in the activity of PLC-72 was 
observed during the time-course of PMA-induced differentia- 
tion. The rate of proliferation of PMA-treated cells was com- 
pared with that of control cells by determining the number of 
cells after the addition of PMA to cultures. Control U937 cells 
with the initial cell number of 2 x 10 6 proliferated exponentially 
in liquid culture. However, no proliferation and the complete 
cessation of cell division in PMA-treated cells became evident 
after 24 h as shown in Fig. lB. This result demonstrated that 
the time course of the loss of proliferation of PMA-treated cells 
was closely correlated with that of the decrease of the PLC-yl  
activity, suggesting that the reduction of PLC-y l  activity may 
be an important step in PMA-induced differentiation of U937 
cells. 
In order to analyze the relationship between the induction of 
differentiation and PLC-y l  or -),2 expression in U937 cells, we 
examined the protein levels of PLC-y l  and -72 during a time 
course of PMA-induced differentiation. Protein level of PLC- 
71 was 64.1 + 5.2 ng/ml and 14.7 + 1.2 ng/ml at 0 and 60 h after 
PMA treatment, respectively, when determined by radioimmu- 
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noassay (Fig. 2A). Western blot analysis also revealed that 
PLC-T1 decreased ramatically after 36 h of PMA treatment 
(Fig. 2A inset), whereas that of PLC-T2 showed no significant 
change (Fig. 2B). This result is in agreement with the changes 
of the activities in immunecomplexes as hown in Fig. 1. There- 
fore, the decrease of PLC-y1 activity during PMA-induced 
differentiation was clearly due to the down-regulation f pro- 
tein level of PLC-y1. 
Recently, we have found that considerably high level of PLC- 
yl is detected in some colon cancer [7] and familial adenoma- 
tous polyposis tissues [8], suggesting that up-regulation f PLC- 
yl may be involved in cellular proliferation associated with 
tumor progression. Thus, the regulation of PLC-T1 expression 
may play an important role in decisive designation of cellular 
proliferation and growth arrest. In contrast, steady-state ex- 
pression of PLC-T2 may be related to its physiological role in 
differentiated monocyte/macrophages. Indeed, PLC-T2 is 
highly expressed in cells of hematopoietic origin, such as pro- 
myelocytic leukemia HL60 cells, histiocytic leukemia U937 cells 
and B cell lines [17-19]. Moreover, PLC-T2 is involved in some 
functional characteristics such as CD40-mediated signaling 
which plays an important role in B cell survival, memory and 
immunoglobulin isotype switch [20] and immunoglobulin G Fc 
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Fig. 2. Quantitation ofPLC-T1 or -7/2 by radioimmunoassay during the 
PMA-induced ifferentiation of U937 cells. U937 cells were treated 
with 5 nM PMA for various times. The extracts (300/lg/50/~1) were 
incubated with each anti-PLC-yl (A) or -y2 (B) antibody-coated mi- 
crotiter plate and the antibody-PLC complex was quantitated by add- 
ing [2SI-labeled secondary antibody (20,000 cprrdwell) in phosphate 
buffered saline containing 5% bovine serum albumin. All samples were 
assayed intriplicate. Insets." Western blot analysis of PLC-T 1 (A) or -y2 
(B) expression. Cell lysates were immunoprecipitated an immunecom- 
plexes were subjected to8% SDS-polyacrylamide gels, transferred onto 
nitrocellulose membrane, and probed with relevant antibodies followed 
by alkaline phosphatase conjugated goat anti-mouse Ig. 
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Fig. 3. Northern blot analysis of PLC-yl or -T2 expression i  U937 cells 
before and after differentiation with PMA. U937 cells were treated 
without (Control) or with (PMA) 5 nM PMA for 72 h. Total RNA was 
purified by acid phenol methods. Fifteen ~tg of total RNA was hybrid- 
ized to the 32p-labeled cDNA of PLC-y1 (A) or PLC-y2 (B). Hybridiza- 
tion of the same filter with fl-actin probe(C) is shown as a control. 
receptor (FcyRIIIA)-initiated signal transduction that medi- 
ates the antibody-dependent cellular toxicity in natural killer 
cells [21]. 
We ask whether the down-regulation f PLC-z1 protein level 
came from transcriptional or translational regulation. The ef- 
fect of PMA on the level of PLC-TI transcript was examined. 
U937 cells were treated without or with PMA for 72 h and then 
the level of PLC-T1 transcript was examined with Northern 
blot analysis using the cDNA of PLC-y1 as a probe. As shown 
in Fig. 3, mRNA level of PLC-T1 remained unchanged during 
PMA-induced differntiation. Therefore, this result suggests 
that differentiation-induced down-regulation f PLC-T1 pro- 
tein may be controlled by the posttranscriptional events rather 
than by transcriptional level. 
In conclusion, we have found that the level of PLC-T1 pro- 
tein markedly decreased but not PLC-z2 during PMA-induced 
differentiation process. From these results, it could be assumed 
that down-regulation f PLC-T1 may be an important step in 
differentiation f U937 cells by PMA. 
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